p53 mutations are common in human papillomavirus type 38-positive non-melanoma skin cancers

Cancer Letters

Volumn 209, Issue 1, 2004, Pages 119-124

  Caldeira, Sandra ^a   Filotico, Raffaele ^b   Accardi, Rosita ^c   Zehbe, Ingeborg ^d   Franceschi, Silvia ^c   Tommasino, Massimo ^c  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY OF BARI   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

E6; Human papillomavirus; Non melanoma skin cancer; p53

Indexed keywords

PROTEIN P53;

ARTICLE; CONTROLLED STUDY; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; NON MELANOMA SKIN CANCER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN CANCER; SKIN CARCINOGENESIS; VIRUS STRAIN; VIRUS TYPING; VIRUS VIRULENCE; WART VIRUS;

ANIMALS; CELLS, CULTURED; COCULTURE TECHNIQUES; CODON; DNA; EXONS; FIBROBLASTS; GENES, P53; IMMUNOBLOTTING; KERATINOCYTES; MUTATION; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; RATS; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 38; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 2442496574     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.12.003     Document Type: Article

References (23)

1. de Villiers E.M. Papillomavirus and HPV typing. Clin. Dermatol. 15:1997;199-206
2. zur H. Hausen Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer. 2:2002;342-350
3. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19:2002;607-614
4. Berkhout R.J., Tieben L.M., Smits H.L., Bavinck J.N., Vermeer B.J., ter Schegget J. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J. Clin. Microbiol. 33:1995;690-695
5. Berkhout R.J., Bouwes Bavinck J.N., ter Schegget J. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J. Clin. Microbiol. 38:2000;2087-2096
6. Caldeira S., Zehbe I., Accardi R., Malanchi I., Dong W., Giarre M., et al. The E6 and E7 proteins of cutaneous human papillomavirus type 38 display transforming properties. J. Virol. 77:2003;2195-2206
7. de Villiers E.M., Lavergne D., McLaren K., Benton E.C. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int. J. Cancer. 73:1997;356-361
8. Shamanin V., zur Hausen H., Lavergne D., Proby C.M., Leigh I.M., Neumann C., et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients see comments. J. Natl Cancer. Inst. 88:1996;802-811
9. Ananthaswamy H.N., Pierceall W.E. Molecular alterations in human skin tumors. Prog. Clin. Biol. Res. 376:1992;61-84
10. Zehbe I., Wilander E., Delius H., Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58:1998;829-833
11. Giarre M., Caldeira S., Malanchi I., Ciccolini F., Leao M.J., Tommasino M. Induction of pRb degradation by the human papillomavirus type 16 E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J. Virol. 75:2001;4705-4712
12. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:2000;81-137
13. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA. 100:2003;8424-8429
14. Zhang W., Funk W.D., Wright W.E., Shay J.W., Deisseroth A.B. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene. 8:1993;2555-2559
15. Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. Eur. Mol. Biol. Org. J. 13:1994;3496-3504
16. Campomenosi P., Monti P., Aprile A., Abbondandolo A., Frebourg T., Gold B., et al. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene. 20:2001;3573-3579
17. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell Biol. 21:2001;1874-1887
18. Pugacheva E.N., Ivanov A.V., Kravchenko J.E., Kopnin B.P., Levine A.J., Chumakov P.M. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene. 21:2002;4595-4600
19. Padlewska K., Ramoz N., Cassonnet P., Riou G., Barrois M., Majewski S., et al. Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis. J. Invest. Dermatol. 117:2001;935-942
20. Steger G., Pfister H. In vitro expressed HPV 8 E6 protein does not bind p53. Arch. Virol. 125:1992;355-360
21. Armstrong B.K., Kricker A. The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B. 63:2001;8-18
22. Ananthaswamy H.N., Loughlin S.M., Cox P., Evans R.L., Ullrich S.E., Kripke M.L. Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens. Nat. Med. 3:1997;510-514
23. Butz K., Denk C., Ullmann A., Scheffner M., Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl Acad. Sci. USA. 97:2000;6693-6697